Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome

Journal of Endocrinological Investigation

Volumn 19, Issue 10, 1996, Pages 687-692

  Beccaria, L ^a,b   Benzi, F ^a   Sanzari, A ^a   Bosio, L ^a   Brambilla, P ^a   Chiumello, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Clin Pediatrics III H San Raffaele   (Italy)

Author keywords

Growth hormone; Growth hormone releasing hormone; Obesity; Prader Labhardt Willi syndrome; Pyridostigmine

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PYRIDOSTIGMINE; SERMORELIN;

ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FLUSHING; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOTENSION; MALE; NEUROENDOCRINE SYSTEM; OBESITY; ORAL DRUG ADMINISTRATION; PRADER WILLI SYNDROME; SCHOOL CHILD; SIDE EFFECT;

EID: 0030468164     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349040     Document Type: Article

References (32)

1. Ritzé E.M., Bolme P., Hall K. Endocrine physiology and therapy in Prader-Willi Syndrome. In: Cassidy S.B. (Ed.), Prader-Willi Syndrome and other Chromosome 15q Deletion Disorders. Springer-Verlag, Berlin, Heidelberg, 1992, NATO ASI series, series H Cell Biology, vol. 61, p. 153.
2. Lee P.D.K., Wilson D.M., Rountree L., Hintz R.L., Rosenfeld R.G. Linear growth response to exogenous growth hormone in Prader-Willi Syndrome. Am. J. Med. Genet. 28: 865, 1987.
3. Costeff H., Holm V.A., Ruvalcaba R., Shaver J. Growth hormone secretion in Prader-Willi Syndrome. Acta Paediatr. Scand. 79: 1059, 1990.
4. Blichfeldt S., Main K., Ritzen M., Skakkebaek N.E. Diminished 24 hour urinary growth hormone excretion in patients with Prader-Willi Syndrome. In: Cassidy S.B. (Ed.), Prader-Willi Syndrome and other Chromosome 15q Deletion Disorders. Springer-Verlag, Berlin Heidelberg, 1991, NATO ASI series, series H Cell Biology, vol. 61, p. 175.
5. Angulo M., Castro-Magana M., Uy J., Rosenfeld W. Growth hormone evaluation and treatment in Prader-Willi Syndrome. In: Cassidy S.B. (Ed.), Prader-Willi Syndrome and other Chromosome 15q Deletion Disorders. Springer-Verlag, Berlin, Heidelberg, 1992, NATO ASI series, series H Cell Biology, vol. 61, p. 171
6. Klish W., Brown B., Lin T., Lee P., Greenberg F. Studies of body composition in patients with PraderWilli Syndrome: implication for management. Am. J. Med. Genet. 41: 524, 1991.
7. Ruvalcaba R.H.A., Holm V.A. Effects of growth hormone in Prader-Willi Syndrome: a case report. Clin. Pediatr. 32: 292, 1993.
8. Loche S., Cappa M., Borrelli P., Faedda A., Crino A., Cella S.G., Corda R., Müller E.E., Pintor C. Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-C mediated inhibition. Clin. Endocrinol. (Oxf.) 27: 145, 1987.
9. Williams T., Berelowitz M., Joffe S.N., Thorner M.O., Rivier J., Vale W., Frohman L.A. Impaired growth hormone responses to growth hormone-releasing factor in obesity: a pituitary defect reversed with weight reduction. N. Engl. J. Med. 311: 1403, 1984.
10. Kopelman P., Noonan K., Goulton R., Forrest A.J. Impaired growth hormone response to growth hormone releasing factor and insulin-hypoglycemia in obesity. Clin. Endocrinol. (Oxf.) 23: 87, 1985.
11. Cordido F., Casanueva F.F., Dieguez C. Cholinergic receptor activation by pyridostigmine restores growth hormone responsiveness to growth hormone-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. J. Clin. Endocrinol. Metab. 68: 290, 1989.
12. Ghigo E., Mazza E., Corrias A., Imperiale E., Goffi S., Arvat E., Bellone J., De Sanctis C., Müller E.E., Camanni F. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children. Metabolism 38: 631, 1989.
13. Ghigo E., Procopio M., Boffano G.M., Arvat E., Valente F., Maccano M., Mazza E., Camanni F. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism 41: 560, 1992.
14. Loche S., Pintus S., Cella S.G., Boghen M., Vannelli V., Benso L., Müller E.E., Corda R., Pintor C. The effect of galanin on baseline and GHRH-induced growth hormone secretion in obese children. Clin. Endocrinol. (Oxf.) 33: 187, 1990.
15. Cappa M., Grossi A., Borrelli P., Ghigo E., Bellone J., Benedetti S., Carta D., Loche S. Growth hormone (GH) response to combined Pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhardt-Willi syndrome. Horm. Res. 39: 51, 1993.
16. Holm V.A., Cassidy S.B., Butler M.G., Hanchett J.M. Greenswag L.R., Whitman B.Y., Greenberg F. Prader-Willi Syndrome: consensus diagnostic criteria. Pediatrics 91: 398, 1993.
17. Ghigo E., Mazza E., Imperiale E., Mohnatti P., Bertagna A., Camanni F., Massara F. Growth hormone responses to pyridostigmine in normal adults and in normal and short children. Clin. Endocrinol. (Oxf.) 27: 669, 1987.
18. Dammacco F., Boghen M.F., Camanni F., Cappa M., Ferrari C., Ghigo E., Giordano G., Loche S., Minuto F., Mucci M., Müller E.E., The Italian Collaborative Group of Neuroendocrinology. Somatotropic function in short stature: evaluation by integrated auxological and hormonal indices in 214 children. J. Clin. Endocrinol. Metab. 77: 68, 1993.
19. Copinschi G., Wegienka L.C., Hane S., Forsham P.H. Effect of arginine on serum levels of insulin and growth hormone in obese subjects. Metabolism 16: 485, 1967.
20. Tanaka K., Inoue S., Shiraki J., Shishido T., Saito M., Numata K., Takamura Y. Age-related decrease in plasma growth hormone: response to growth hormone-releasing hormone, arginine, and L-Dopa in obesity. Metabolism 40: 1257, 1991.
21. Muruais C., Cordido F., Morales M.J., Casanueva F.F., Diéguez C. Corticosteroid-induced growth hormone secretion in normal and obese subjects. Clin. Endocrinol. (Oxf.) 35: 485, 1991.
22. Castro R., Vieria J., Chacra A., Grossman A., Besser M., Lengyel A. Pyndostigmine enhances but does not normalise the GH response to GH-releasing hormone in obese subjects. Acta Endocrinol. (Copenh.) 122: 385, 1990
23. Ghigo E., Goffi S., Arvat E., Imperiale E., Boffano G.M., Valetto M.R., Mazza E., Santi L., Magliona A., Boghen M.F., Boccuzzi G., Camanni F. A neuroendocrinological approach to evidence an impairment of central cholmergic function in aging. J. Endocrinol. Invest. 15: 665, 1992.
24. Ho K.K.Y. Aging and growth hormone. Horm. Res. 40: 80, 1993.
25. Ghigo E., Nicolosi M., Arvat E., Marcone A., Danelon F., Mucci M., Franceschi M., Smirne S., Camanni F. Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine Dementia 4: 315, 1993.
26. Ghigo E., Arvat E., Gianotti L. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. Biol. Psychiatry 36: 1, 1994.
27. Alba-Roth J., Múller O.A., Schopohl J., von Werder K. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatm secretion. J Clin. Endocrinol. Metab. 67: 1186, 1988.
28. Davies P.S.W., Joughin C. Assessment of body composition in the Prader-Willi Syndrome using bioelectrical impedance. Am. J. Med. Genet. 44: 75, 1992.
29. De Boer H., Blök G.J., Voerman H.J. De Vries P.M.J.M., Van der Veen E.A. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J. Clin. Endocrinol. Metab. 75: 833, 1992.
30. Salomon F., Cuneo R.C., Hesp R., Sönksen P.H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321: 1797, 1989.
31. Foster G.D., Wadden T.A., Müllen J.L., Stunkard A.J., Wang J., Feurer I.D., Pierson R.N., Yang M.U., Presta E., Van Itallie T.B., Lemberg P.S., Gold J. Resting energy expenditure, body composition, and excess weight in the obese. Metabolism 37: 467, 1988.
32. Juul A., Bang P., Hertel N.T., Main K., Dalgaard P., Jørgensen K., Müller J., Hall K., Skakkebaek N.E. Serum insulin-like growth factor-1 in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J. Clin. Endocrinol. Metab. 78: 744, 1994.